Omega-3s May Impact Gut Microbiota, Protect Against Colorectal Cancer
Feb 4, 2019
Results of an open label study on omega-3 PUFA supplementation found a small but transient effect on gut microbiota that could warrant future research.
Recent Content
Can CHA2DS2-VASc Predict Recurrence of Atrial Fibrillation?
Feb 4, 2019
Atrial fibrillation recurrence remains a challenge amidst significant advances in managing stroke risk. Could the CHA2DS2-VASc score help?
Diabetes Drugs and CV Protection: An 8-question Quiz
Jan 8, 2019
How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.
Dapagliflozin Helps Prevent HF Hospitalization in T2D without CVD
Dec 13, 2018
SGLT-2 inhibitors appear to have a more consistent effect on prevention of HF and renal outcomes than on atherosclerotic CV events, say study authors.
Fish Oil Prescribed vs Fish Oil Taken: A First Look
Dec 11, 2018
Among lipid clinic patients, actual EPA+DHA supplement intake was <50% of prescribed dosage, according to the first study to look at the association.
Triglycerides and EPA: A New Chapter in CV Disease Prevention
Nov 20, 2018
Findings from REDUCE-IT are the first to show that EPA lowers the relative risk of hard cardiovascular endpoints. Johns Hopkins' Seth Martin, MD, and colleagues put the trial in perspective.
Cardio Quiz: Cardiorenal Syndromes are Not Created Equal
Nov 12, 2018
Cardiorenal syndrome has 5 subtypes that are each sbudivided as well. This quiz focuses on type 4--so cardiologists and nephrologists, unite!
ASCEND Study: Could Results be Swan Song for Fish Oil?
Nov 12, 2018
Fish oil or fish for CV protection? It's a well studied yet unresolved question. Highlights, here, of the ASCEND study and all those that came before.
CKD Patients with STEMI: High-risk yet Under the Radar
Oct 25, 2018
Patients with renal disease are poorly represented in studies of treatment for STEMI but, a new study finds, are at much greater risk for MACE and death.
Cardio-oncology or Onco-cardiology? Take your Pick
Oct 15, 2018
Either one is fine – the point is to make sure the practice stays a step ahead of the next new drug class causing the problem.
